Kendomycin is primarily studied for its potential in cancer therapy due to its ability to inhibit cell proliferation and induce apoptosis in various cancer cell lines. Its unique mechanism of action involves targeting specific cellular pathways, making it a promising candidate for developing novel anticancer drugs. Additionally, kendomycin exhibits antibacterial properties, particularly against Gram-positive bacteria, which could lead to its application in combating antibiotic-resistant infections. Research is ongoing to explore its full therapeutic potential and optimize its efficacy in clinical settings.